News
CLNN
0.4254
+0.09%
0.0004
Weekly Report: what happened at CLNN last week (0318-0322)?
Weekly Report · 4d ago
Clene Price Target Maintained With a $5.00/Share by Benchmark
Dow Jones · 03/20 12:35
Benchmark Reiterates Buy on Clene, Maintains $5 Price Target
Benzinga · 03/20 12:25
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)
TipRanks · 03/20 11:21
Weekly Report: what happened at CLNN last week (0311-0315)?
Weekly Report · 03/18 11:55
Buy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market Dynamics
TipRanks · 03/15 17:45
Clene Announces Peer-Reviewed Publication Characterizing Protein Corona Of Investigational Neurodegenerative Disease Drug, CNM-Au8
Protein corona attracted by CNM-Au8 nanocrystals prevents aggregation upon entering the bloodstream. Nanocrystals develop a protein corona upon exposure to human blood plasma. The corona promotes blood-brain barrier penetration, an important feature of the drug's neuroprotective mechanism.
Benzinga · 03/15 12:03
Breaking Down Clene: 4 Analysts Share Their Views
Clene (NASDAQ:CLNN) has been analyzed by 4 analysts in the last three months. The company is a clinical-stage pharmaceutical company pioneering the development of novel clean-surfaced nanotechnology. Clene has an average 12-month price target of $7.0.
Benzinga · 03/13 19:00
Clene Inc. reports results for the quarter ended in December - Earnings Summary
Clene Inc. Reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 6 cents per share. Revenue fell 27.4% to $170.00 thousand from a year ago. Clene Inc.'s shares had risen by 49.7% this quarter.
Reuters · 03/13 14:37
Clene: Q4 Earnings Insights
Clene reports its Q4 earnings results on March 13. The company beat estimates by 86.0% Clene's revenue was down $64 thousand from the same period last year. Clene is expected to report earnings of $-0.01 per share. Last quarter Clene beat on EPS by $0.07 and the share price dropped 1.0%.
Benzinga · 03/13 13:40
Clene FY GAAP EPS $(0.47) Misses $(0.46) Estimate, Sales $654.00K Beat $557.00K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $0.47 per share. The company missed the analyst consensus estimate by 2.17 percent. Clene reported quarterly sales of $654.00 thousand which is a 38.27 percent increase over the same period last year.
Benzinga · 03/13 12:10
Press Release: Clene Reports Full Year 2023 -2-
Research and development expenses were $26.7 million for the year ended December 31, 2023. The company reported a net loss of $49.5 million. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health to treat neurodegenerative diseases. CNM-Au8(R) is an oral suspension of gold nanocrystals.
Dow Jones · 03/13 12:00
Press Release: Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Clene reports full year 2023 financial results and recent operating highlights for the clinical programs in ALS and MS. Company is in discussions with FDA regarding accelerated approval pathway for CNM-Au8(R) for the treatment of ALS. Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health.
Dow Jones · 03/13 12:00
Clene: Statement of changes in beneficial ownership of securities
Press release · 03/12 22:04
Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)
TipRanks · 03/11 12:40
HC Wainwright & Co. Maintains Buy on Clene, Maintains $7 Price Target
Benzinga · 03/11 12:28
Weekly Report: what happened at CLNN last week (0304-0308)?
Weekly Report · 03/11 11:50
Weekly Report: what happened at CLNN last week (0226-0301)?
Weekly Report · 03/04 11:54
Buy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical Outcomes
TipRanks · 02/29 15:25
Clene Announces Breakthrough CNM-Au8 Treatment Results
TipRanks · 02/29 13:23
More
Webull provides a variety of real-time CLNN stock news. You can receive the latest news about Clene through multiple platforms. This information may help you make smarter investment decisions.
About CLNN
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.